

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 November 2023 (23.11.2023)



(10) International Publication Number

WO 2023/222557 A1

(51) International Patent Classification:

A61K 51/10 (2006.01) A61K 31/4155 (2006.01)
A61P 35/00 (2006.01) A61K 45/06 (2006.01)
C07K 16/30 (2006.01)

(21) International Application Number:

PCT/EP2023/062860

(22) International Filing Date:

13 May 2023 (13.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22173871.9 17 May 2022 (17.05.2022) EP
22199703.4 05 October 2022 (05.10.2022) EP
23164865.0 29 March 2023 (29.03.2023) EP

(71) Applicants: **BAYER AKTIENGESellschaft**
[DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen
(DE). **BAYER AS** [NO/NO]; Drammensveien 288, 0283
Oslo (NO).

(72) Inventors: **SCHATZ, Christoph**; Crioloweg 26, 13465
Berlin (DE). **ZITZMANN-KOLBE, Sabine**; Seppenrader
Weg 15, 13507 Berlin (DE). **LARSEN, Aasmund**; c/o Bay-
er AS, Drammensveien 288, 0283 Oslo (NO). **RYAN, Olav
B.**; c/o Bayer AS, Drammensveien 288, 0283 Oslo (NO).
INDREVOLL, Bard; c/o Bayer AS, Drammensveien 288,
0283 Oslo (NO). **CUTHBERTSON, Alan**; c/o Bayer AS,
Drammensveien 288, 0283 Oslo (NO). **BJERKE, Roger
Malerbakken**; c/o Bayer AS, Drammensveien 288, 0283
Oslo (NO). **MOEN, Ingrid**; c/o Bayer AS, Drammensveien
288, 0283 Oslo (NO). **HAENDLER, Bernard**; Am Biber-
bau 8, 13465 Berlin (DE). **HAGEMANN, Urs Beat**; Son-
nenblumenweg 20a, 16548 Glienicke/Nordbahn (DE).

(74) Agent: **BIP PATENTS**; c/o Bayer Intellectual Property
GmbH, Alfred-Nobel-Straße 50, 40789 Monheim am Rhein
(DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS
COMBINATIONS



(57) Abstract: The present invention relates to tissue-targeting com-
pounds. In particular, the present invention relates to tissue-targeting
compounds comprising a monoclonal antibody or an antigen-bind-
ing fragment thereof having binding affinity for the prostate-specific
membrane antigen (PSMA). Further, the present invention relates to
combinations, preferably pharmaceutical combinations comprising
a tissue-targeting compound of formula (I) and a further pharmaceu-
tical agent. Said combinations are useful in therapy, preferably in
treating hyperproliferative diseases such as cancer.

WO 2023/222557 A1